FAKTOR-OPTIONSSCHEIN - AGIOS PHARMA Share Price

Certificat

DE000MG2XTR9

Market Closed - Börse Stuttgart 12:19:28 29/06/2024 am IST
18.15 EUR -3.71% Intraday chart for FAKTOR-OPTIONSSCHEIN - AGIOS PHARMA
Current month+24.32%
1 month+73.02%
Date Price Change
28/24/28 18.15 -3.71%
27/24/27 18.85 +2.45%
26/24/26 18.4 -7.21%
25/24/25 19.83 -0.85%
24/24/24 20 +14.22%

Delayed Quote Börse Stuttgart

Last update June 29, 2024 at 12:19 am IST

More quotes

Static data

Product typeProduits Exotiques
Buy / SellCALL
Underlying AGIOS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MG2XTR
ISINDE000MG2XTR9
Date issued 24/04/2024
Strike 21.81 $
Maturity Unlimited
Parity 1.1 : 1
Emission price 10
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 23.02
Lowest since issue 10.38
Spread 0.17
Spread %0.94%

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Sector
-
More about the company

Ratings for Agios Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Agios Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
43.12 USD
Average target price
52.83 USD
Spread / Average Target
+22.53%
Consensus